Diagnosis & Disease Information

Hodgkin’s Lymphoma Survivors Face Higher Diabetes Risk

August 27, 2014

Para-aortic radiation with ≥36 Gy linked to increased risk of diabetes mellitus.

Lymphoma and Chronic Lymphocytic Leukemias

Hematologic Cancers

New Therapies in T-cell Lymphoma

By

G.P. Collins, D. Bruce, and T.A. Eyre

August 21, 2014

[Lymphoma and Chronic Lymphocytic Leukemias] Biomarker-driven chemotherapeutics is becoming a critical part of the state-of-the-art treatment in clinical trials involving patients with T-cell lymphoma.

Slides

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

August 15, 2014

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 7: Use in Specific PopulationsSlide 9: Clinical PharmacologySlide 13: Warnings and PrecautionsSlide 18: Clinical Safety and EfficacySlide 24: Drug Storage and SupplySlide 26: References

Preventive therapy for ER-negative breast cancer

Mocetinostat Receives Orphan Drug Status

August 11, 2014

The FDA has granted Orphan Drug Designation to mocetinostat for diffuse large B-cell lymphoma.

For Lymphoma Patients Receiving R-CHOP, Entecavir More Effective for HBV-Related Hepatitis Prophylax

Potential New Treatment Options for Drug-Resistant Mantle Cell Lymphoma

August 1, 2014

Genomic analyses provided explanations for these two types of drug resistance and suggested ways to overcome them.

The COG guidelines focus on reproductive health for young cancer survivors

Sperm Production Harmed by Lymphoma Treatment

July 28, 2014

Treatment for lymphoma may lower men’s fertility, new research indicates.

Arzerra Fails Late-stage Trial

Hematologic Cancers

FDA Approves Zydelig for Three Hematologic Cancers

July 23, 2014

The FDA has approved Zydelig for relapsed chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.

Nivolumab Designated Breakthrough Therapy for Hodgkin Lymphoma

Patients With Hodgkin Lymphoma May Develop Third Malignancy

July 21, 2014

Hodgkin lymphoma survivors who have developed a second malignancy are at a higher risk of developing a third malignancy.

Potential Therapy for Rare, Drug-resistant GISTs

Beleodaq Earns FDA Approval for Peripheral T-cell Lymphoma

July 3, 2014

The FDA has approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma.

Abbreviated Protocol Feasible in Breast Cancer MRI Screening

Clinical Surveillance Possible in Classical Hodgkin Lymphoma After Remission

July 3, 2014

Survival rate for patients who underwent clinical surveillance was similar those who underwent routine surveillance imaging.

Next post in Lymphoma

New Drug May Be Game-Changer for AML

New Routine Testing for Non-Hodgkin Lymphomas Recommended